Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
CAMBRIDGE, Mass., Aug. 31, 2017 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN) today announced that Anna Protopapas, President and Chief Executive Officer, will participate in three upcoming investor conferences in September. Details are as follows:
Baird 2017 Global Healthcare Conference
Date/time: Wednesday, September 6th at 3:10 p.m. E.T.
Location: New York, NY
Cantor Fitzgerald Global Healthcare Conference
Date/time: Wednesday, September 27th at 3:25 p.m. E.T.
Location: New York, NY
Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Date/time: Thursday, September 28th at 8:00 a.m. E.T.
Location: New York, NY
Live webcasts of the presentations will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 60 days following the presentations.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1522, is in Phase I clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company expects that its second product candidate, XMT-1536, will enter clinical trials in early 2018. In addition, multiple partners are using Mersana’s leading platform to advance their ADC pipelines.
Media Contact Paul Kidwell [email protected] 617-680-1088 Investors Contact Stern Investor Relations, Inc. Christina Tartaglia [email protected] (212) 362-1200
